Chapter 14: Signal-Transduction Pathways

Signal-Transduction Pathways summary explores the molecular architecture of signal-transduction pathways, the essential information circuits that allow cells to perceive and respond to environmental stimuli through the reception, transduction, and amplification of signals. The text details the fundamental logic of these pathways, beginning with the release of primary messengers (ligands) and their interaction with cell-surface receptors, which transfer information into the cell interior. A major focus is placed on Seven-Transmembrane-Helix (7TM) receptors, also known as G-protein-coupled receptors (GPCRs), exemplified by the beta-adrenergic receptor's response to epinephrine. This section elucidates how ligand binding triggers conformational changes that activate heterotrimeric G proteins by exchanging GDP for GTP, subsequently stimulating adenylate cyclase to produce cyclic AMP (cAMP). The summary explains how this second messenger activates Protein Kinase A (PKA) to regulate metabolic targets, and how the signal is eventually terminated through intrinsic GTPase activity and receptor desensitization by beta-arrestin. The discussion expands to the phosphoinositide cascade, another GPCR mechanism where phospholipase C generates inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), leading to calcium release from the endoplasmic reticulum and the activation of Protein Kinase C (PKC). The critical role of calcium as a ubiquitous second messenger, sensed by EF-hand proteins like calmodulin, is also highlighted. The summary then shifts to Receptor Tyrosine Kinases (RTKs), contrasting the insulin receptor and the epidermal growth factor (EGF) receptor. It details how insulin binding induces cross-phosphorylation within a pre-existing receptor dimer, recruiting adaptor proteins like IRS-1 and activating lipid kinases such as phosphoinositide 3-kinase (PI3K) to generate PIP3 and activate Akt (Protein Kinase B). Conversely, the EGF pathway serves as a model for ligand-induced dimerization, activating the small G protein Ras via adaptor proteins like Grb2 and Sos, which triggers a phosphorylation cascade involving Raf, MEK, and ERK to alter gene expression. The text emphasizes recurring modular protein domains, such as SH2, SH3, and Pleckstrin Homology (PH) domains, which facilitate specific protein-protein interactions. Finally, the summary connects defects in these signaling pathways to pathological states, discussing how mutations in proto-oncogenes (like ras and src) and tumor suppressors contribute to cancer, how bacterial toxins (cholera and pertussis) disrupt G-protein cycling, and how modern therapeutics like the kinase inhibitor Gleevec and monoclonal antibodies (Trastuzumab, Cetuximab) target specific signaling aberrations to treat disease.